Does Ozempic Cause Gastroparesis? A Review of Evidence and Risk

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Drug Safety Inquiry

For decades, public health communication has centered on general wellness and the broad dissemination of scientific knowledge. This legacy heritage, rooted in accessible health information, has empowered individuals to make informed decisions about common conditions and preventive care. Within this framework, discussions of medication side effects have traditionally focused on acute reactions or well-documented risks, often within the context of chronic disease management. As the landscape of therapeutics evolves, so too must the scope of health inquiry. The widespread use of newer classes of medications, such as GLP-1 receptor agonists, has introduced a need to examine potential long-term effects beyond their primary indications. This shift moves the conversation from general health maintenance toward a more targeted occupational and clinical exposure concern: understanding the relationship between sustained drug exposure and the development of specific adverse outcomes. In this context, the question of whether Ozempic exposure may be associated with gastroparesis risk emerges as a critical point of focus. Transitioning from a broad health information paradigm, we now pivot to examining how prolonged pharmacological exposure in patient populations might correlate with gastrointestinal motility disorders. This reframing acknowledges the need for careful surveillance and risk assessment in clinical practice, without venturing into mechanistic speculation.

Clinical Trial Data and Adverse Event Reporting

The question of whether Ozempic (semaglutide) causes gastroparesis requires careful examination of available clinical trial data and adverse event reporting. Gastroparesis is a condition characterized by delayed gastric emptying, leading to symptoms such as nausea, vomiting, abdominal pain, and early satiety. While Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist known to slow gastric motility as part of its mechanism of action, the specific link to clinical gastroparesis is not explicitly established in the prescribing information. Clinical trial data from the Ozempic label indicate that gastrointestinal adverse reactions are common. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific gastrointestinal adverse reactions reported with a frequency of less than 5% include dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Notably, the term 'gastroparesis' does not appear in the label's adverse reactions section. However, the symptoms of gastroparesis—such as nausea, vomiting, and dyspepsia—overlap with the gastrointestinal effects reported. The label does not provide a specific diagnosis of gastroparesis in clinical trials, but the mechanistic slowing of gastric emptying by GLP-1 receptor agonists is well-documented.

Mechanistic Plausibility and Label Warnings

From a mechanistic perspective, GLP-1 receptor agonists like semaglutide delay gastric emptying, which can contribute to symptoms that mimic or exacerbate gastroparesis. The label's warnings and cautions section does not specifically address gastroparesis but does include a warning about hypersensitivity reactions, such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This omission suggests that the FDA has not required a specific warning for gastroparesis based on current evidence. Regarding risk considerations, the adequacy of warnings for gastroparesis is limited. The label does not explicitly mention gastroparesis as an adverse reaction, which may leave patients and clinicians unaware of the potential for this condition. For affected patients, causation considerations are complex. The timeline between exposure and documented harm is not clearly defined in the label, but gastrointestinal adverse reactions are most common during dose escalation, suggesting an early onset. However, delayed gastric emptying can persist with continued use, and symptoms may develop or worsen over time. For patients who experience severe or persistent gastrointestinal symptoms, discontinuation of Ozempic may be necessary. The label notes that more patients on Ozempic discontinued due to gastrointestinal adverse reactions compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Clinicians should monitor for signs of gastroparesis, such as postprandial fullness, nausea, vomiting, and abdominal pain, especially in patients with pre-existing gastrointestinal conditions. In summary, while Ozempic does not have a specific label warning for gastroparesis, its pharmacological effect of delaying gastric emptying and the high incidence of gastrointestinal adverse reactions suggest a plausible link. The evidence does not confirm causation in a strict sense, but the association is supported by mechanistic plausibility and clinical trial data. Patients and healthcare providers should be aware of this potential risk and monitor symptoms accordingly.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it related to Ozempic?

Gastroparesis is a condition characterized by delayed gastric emptying, leading to symptoms like nausea, vomiting, abdominal pain, and early satiety. Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric motility as part of its mechanism. While the drug label does not explicitly list gastroparesis as an adverse reaction, the overlapping symptoms and pharmacological effect suggest a plausible link. Clinical trials show high rates of gastrointestinal adverse reactions, but specific gastroparesis diagnosis was not reported.

Does the Ozempic label include a warning for gastroparesis?

No, the Ozempic label does not include a specific warning for gastroparesis. The warnings section covers hypersensitivity reactions but not gastroparesis. However, the label reports common gastrointestinal adverse reactions such as nausea, vomiting, and dyspepsia, which are also symptoms of gastroparesis. The absence of a specific warning may limit awareness among patients and clinicians.

What should patients do if they experience severe gastrointestinal symptoms while taking Ozempic?

Patients experiencing severe or persistent gastrointestinal symptoms such as nausea, vomiting, abdominal pain, or early satiety should consult their healthcare provider. The Ozempic label indicates that more patients discontinued due to gastrointestinal adverse reactions compared to placebo. Clinicians may consider monitoring for signs of gastroparesis and, if necessary, discontinuing Ozempic. Patients should not stop medication without medical advice.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.